Intellectual Property Protection
The Congress in Uruguay approved the bill presented by the Executive in December 1997. It is deficient and contrary to the interests of the research-based pharmaceutical industry. In the most general terms:
- Compulsory licensing is very broadly established;
- Data exclusivity is omitted;
- Exclusive marketing rights are not considered;
- Pipeline patent protection is not considered;
- Parallel importation is allowed.
Potential Export/Foreign Sales
The removal of current barriers would mean an increase in sales and exports in the range of US$50 million to US$100 million for PhRMA members.